Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 67.00% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 14.95B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 41.40%.
Undervalued
The company’s latest PE is 33.50, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 575.83M shares, increasing 2.05% quarter-over-quarter.
Held by First Eagle Investment
Star Investor First Eagle Investment holds 105.83M shares of this stock.